R A Middelburg1, L Porcelijn, N Lardy, E Briët, H Vrielink. 1. Department of Clinical Epidemiology and Einthoven Laboratory, Leiden University Medical Center, Leiden, The Netherlands. R.Middelburg@Sanquin.nl
Abstract
INTRODUCTION: Donor leucocyte antibodies have been associated with transfusion-related acute lung injury (TRALI) and can be present in allo-exposed donors. Donor deferral policies aiming at excluding allo-exposed donors are increasingly implemented worldwide. We aimed at assessing the prevalence of leucocyte antibodies in different subgroups of allo-exposed donors in the Dutch donor population. METHODS: Consecutive donors were enrolled during routine whole blood donation. Donors filled out a questionnaire on allo-exposure history. Blood samples were tested for human leucocyte antigens (HLA) (LifeScreen Deluxe and the Lifecodes LSA I/II assays) and granulocyte-reactive (GIFT, GAT, and MAIGA) antibodies. RESULTS: Six thousand and thirty-four consecutive donors (60% men) were included. A total of 2.5% reported a history of blood transfusions, and 51% (of female donors) reported a history of pregnancy. In never allo-exposed donors, the prevalence of granulocyte-reactive antibodies was 2.0% (95% CI: 1.6-2.4), and for HLA antibodies, it was 7.0% (95% CI: 6.3-7.8). In previously pregnant donors, the prevalence of granulocyte-reactive antibodies was increased to 3.0% (95% CI: 2.0-4.0), and for HLA antibodies, it was increased to 33% (95% CI: 30-36). Prevalence of leucocyte antibodies of all types depended on transfusion history, number of pregnancies, time since last pregnancy, and pregnancy outcome. CONCLUSIONS: Fourteen percent of Dutch blood donors are allo-immunized against HLA or granulocyte antigens. Deferral of all self-reported allo-exposed donors will decrease this prevalence to 9%. Deferral of all female donors and transfused male donors will result in a similar prevalence among remaining donors but approximately twice as many deferrals.
INTRODUCTION:Donor leucocyte antibodies have been associated with transfusion-related acute lung injury (TRALI) and can be present in allo-exposed donors. Donor deferral policies aiming at excluding allo-exposed donors are increasingly implemented worldwide. We aimed at assessing the prevalence of leucocyte antibodies in different subgroups of allo-exposed donors in the Dutch donor population. METHODS: Consecutive donors were enrolled during routine whole blood donation. Donors filled out a questionnaire on allo-exposure history. Blood samples were tested for human leucocyte antigens (HLA) (LifeScreen Deluxe and the Lifecodes LSA I/II assays) and granulocyte-reactive (GIFT, GAT, and MAIGA) antibodies. RESULTS: Six thousand and thirty-four consecutive donors (60% men) were included. A total of 2.5% reported a history of blood transfusions, and 51% (of female donors) reported a history of pregnancy. In never allo-exposed donors, the prevalence of granulocyte-reactive antibodies was 2.0% (95% CI: 1.6-2.4), and for HLA antibodies, it was 7.0% (95% CI: 6.3-7.8). In previously pregnant donors, the prevalence of granulocyte-reactive antibodies was increased to 3.0% (95% CI: 2.0-4.0), and for HLA antibodies, it was increased to 33% (95% CI: 30-36). Prevalence of leucocyte antibodies of all types depended on transfusion history, number of pregnancies, time since last pregnancy, and pregnancy outcome. CONCLUSIONS: Fourteen percent of Dutch blood donors are allo-immunized against HLA or granulocyte antigens. Deferral of all self-reported allo-exposed donors will decrease this prevalence to 9%. Deferral of all female donors and transfused male donors will result in a similar prevalence among remaining donors but approximately twice as many deferrals.
Authors: John S Riley; Lauren E McClain; John D Stratigis; Barbara E Coons; Haiying Li; Heather A Hartman; William H Peranteau Journal: J Immunol Date: 2018-07-18 Impact factor: 5.422
Authors: Camila Caram-Deelder; Aukje L Kreuger; Dorothea Evers; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Jaap Jan Zwaginga; Johanna G van der Bom; Rutger A Middelburg Journal: JAMA Date: 2017-10-17 Impact factor: 56.272
Authors: Maaike Rijkers; Anno Saris; Sebastiaan Heidt; Arend Mulder; Leendert Porcelijn; Frans H J Claas; Ruben Bierings; Frank W G Leebeek; A J Gerard Jansen; Gestur Vidarsson; Jan Voorberg; Masja de Haas Journal: Haematologica Date: 2018-06-01 Impact factor: 9.941
Authors: Lorenz Küssel; Harald Herkner; Markus Wahrmann; Farsad Eskandary; Konstantin Doberer; Julia Binder; Petra Pateisky; Harald Zeisler; Georg A Böhmig; Gregor Bond Journal: Sci Rep Date: 2017-10-19 Impact factor: 4.379
Authors: Evan M Bloch; Ruchika Goel; Silvano Wendel; Thierry Burnouf; Arwa Z Al-Riyami; Ai Leen Ang; Vincenzo DeAngelis; Larry J Dumont; Kevin Land; Cheuk-Kwong Lee; Adaeze Oreh; Gopal Patidar; Steven L Spitalnik; Marion Vermeulen; Salwa Hindawi; Karin Van den Berg; Pierre Tiberghien; Hans Vrielink; Pampee Young; Dana Devine; Cynthia So-Osman Journal: Vox Sang Date: 2020-07-20 Impact factor: 2.996